Send to

Choose Destination
Am J Med. 2009 Jun;122(6 Suppl):S11-24. doi: 10.1016/j.amjmed.2009.03.013.

Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.

Author information

Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, Vermont 05405, USA.


This article aims to provide an overview of efficacy and safety data on glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus. Our goal is to differentiate the clinical profiles of GLP-1 receptor agonists and DPP-4 inhibitors, as well as the individual agents within each class. Additionally, we examine the utility of GLP-1 receptor agonists and DPP-4 inhibitors as these agents may be applied at different stages of type 2 diabetes therapy and discuss recently published clinical findings and their implications for treatment.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center